Researchers sought to delineate the role of cystic fibrosis transmembrane conductance regulator (CFTR) in pulmonary arterial hypertension pathogenesis through observational and interventional experiments in human tissues and animal models.
Avoiding intubation and mechanical ventilation during subcutaneous pump implantation under local anesthesia and conscious analgosedation was feasible in patients with pulmonary arterial hypertension.
Riociguat may be a useful option for patients with pulmonary arterial hypertension in whom phosphodiesterase-5 inhibitor treatment is insufficient.
Patients with pulmonary arterial hypertension and iron deficiency in the absence of anemia who received iron supplements did not show significant clinical benefit at 12 weeks.
Patients with pulmonary hypertension and COPD appear to have a poorer prognosis than those with idiopathic pulmonary arterial hypertension.
Since uric acid levels in patients with idiopathic pulmonary arterial hypertension are associated with an impaired clinical and hemodynamic profile, they may serve as a useful noninvasive indicator of disease severity.
In pulmonary arterial hypertension, high plasma levels of hepatic growth factor are associated with the right heart maladaptive phenotype and are incremental to the REVEAL score for the prediction of patient outcomes.
Asymptomatic carriers of the BMPR2 mutation have a significant risk of developing incident pulmonary arterial hypertension.
The new diagnostic criteria for pre-capillary pulmonary hypertension may better recognize patients with early forms of pulmonary vascular disease and poor prognosis.
A collection of algorithms for detecting pulmonary arterial hypertension in administrative data has been developed to enhance the integrity and value of research findings and improve quality of care.
